The saying, “you are only as good as the company you keep” also applies to therapeutics like AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap. The company in this case is Dr. Anthony P. Conley, a dedicated and compassionate clinical investigator for whom we at EpicentRx, have the utmost admiration and appreciation.
The direct and proactive involvement of Dr. Conley and his MD Anderson Cancer Center team on the Phase 1/2 clinical trial, BETA PRIME, with AdAPT-001 has a lot to do with how successful it has been in terms of enrollment and the clinical activity that we continue to observe across several tumor types including sarcomas. The latter are a heterogeneous group of rare tumors that develop in the bones and connective tissues, including fat, muscles, blood vessels, and nerves.
Dr. Conley, a sarcoma medical oncologist, at the University of Texas MD Anderson Cancer Center, is a lead author on a soon-to-be presented SITC abstract entitled “AdAPT-001 in Advanced Soft-Tissue Sarcoma (BETA PRIME): A Multicenter, Open-label, Phase 1/2 Clinical Trial (NCT04673942).”
His unwavering commitment to BETA PRIME and to his patients is the reason why Dr. Conley has become, perhaps more so than any other Investigator, the face of AdAPT-001.